{"url_path":"/sec/adgm/8-k/2026-05-21/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/2006986/0001104659-26-065180-index.html","accession_number":"0001104659-26-065180","cik":"0002006986","ticker":"ADGM","issuer_name":"Adagio Medical Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2006986/0001104659-26-065180-index.html","primary_entity_key":"0002006986","primary_entity_name":"Adagio Medical Holdings, Inc."},"word_count":307,"has_tables":true,"body_markdown":"false\n0002006986\n\n0002006986\n\n2026-05-21\n2026-05-21\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES **\n\n**SECURITIES AND EXCHANGE COMMISSION **\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT **\n\n**Pursuant to Section 13 or 15(d) of\nthe Securities Exchange Act of 1934**\n\n \n\n**Date of Report (Date of earliest event reported):\nMay 21, 2026**\n\n \n\n**ADAGIO MEDICAL HOLDINGS, INC.**\n\n**(Exact name of registrant as specified in its\ncharter)**\n\n \n\n**Delaware**\n**001-42199**\n**99-1151466**\n\n(State or other jurisdiction of incorporation)\n(Commission File Number)\n(I.R.S. Employer Identification No.)\n\n \n\n**26051 Merit Circle, Suite 102**\n\n**Laguna Hills, CA**\n\n \n**92653**\n\n(Address of principal executive offices)\n \n(Zip Code)\n\n \n\n**(949) 348-1188 **\n\n(Registrant’s telephone number, including\narea code)\n\n \n\n**Not Applicable **\n\n(Former name or former address, if changed since\nlast report)\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of\nthe Act:\n\n \n\n**Title of each class**\n\n**Trading**\n\n**Symbol(s)**\n\n**Name of each exchange**\n\n**on which registered**\n\nCommon Stock, par value $0.0001 per share\nADGM\nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange\nAct of 1934.\n\n \n\nEmerging growth\ncompany x\n\n \n\nIf an emerging growth\ncompany, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or\nrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}